Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bimatoprost. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR known ✓ | P43088 | 8/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 1/20 | 1.00 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.80 |
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.63 |
| ▸ | MGLL | Q99685 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.59 |
| ▸ | SLCO2A1 | Q92959 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.59 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.57 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bimatoprost SCHEMBL12076310 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL12076308 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL12087441 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL15676045 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL10071736 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL14201686 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL15676044 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL12736967 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL22364345 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL15180642 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150031898-A1 | PROCESS FOR PREPARATION OF PROSTAGLANDIN F2 ALPHA ANALOGUES | INSTYTUT FARMACEUTYCZNY (PL) | 2015-01-29 | — | — | US | disclosed |
| EP-2274279-B1 | NITRIC OXIDE DONATING PROSTAMIDES | NICOX SA (FR) | 2013-07-31 | — | — | EP | disclosed |
| US-8101658-B2 | Nitric oxide donating prostamides | NICOX S.A. (FR) | 2012-01-24 | — | — | US | disclosed |
| US-20110092590-A1 | NITRIC OXIDE DONATING PROSTAMIDES | NICOX S.A. (FR) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031898-A1 | PROCESS FOR PREPARATION OF PROSTAGLANDIN F2 ALPHA ANALOGUES | PTGES, PTGIS, PTGES2 | PTGFR 10/4885ABCB11 2967/4885AKR1C3 505/4885 |
| US-20110092590-A1 | NITRIC OXIDE DONATING PROSTAMIDES | PTGIS, PTGIR, NOS2 | PTGFR 33/4885ABCB11 2484/4885AKR1C3 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.